deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02066415

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention

Sponsor: Amgen

Conditions Treatment for Prevention of Chronic Migraine
Interventions Erenumab Placebo
Updated 14 times since 2017 Last updated: Oct 3, 2022 Started: Mar 5, 2014 Primary completion: Feb 24, 2016 Completion: Apr 28, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Treatment for Prevention of Chronic Migraine and is currently completed. Amgen leads this study, which shows 14 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2019 · 13 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. May 2022 — Sep 2022 [monthly]

    Completed PHASE2

  2. Jan 2021 — May 2022 [monthly]

    Completed PHASE2

  3. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE2

  4. Nov 2019 — Jan 2020 [monthly]

    Completed PHASE2

  5. Aug 2019 — Nov 2019 [monthly]

    Completed PHASE2

  6. Jul 2018 — Aug 2019 [monthly]

    Completed PHASE2

  7. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE2

  8. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amherst, United States , Ann Arbor, United States , Atlanta, United States , Austin, United States , Berlin, Germany , Bochum, Germany , Brno, Czechia , Calgary, Canada , Cleveland, United States , Dallas, United States and 56 more locations